Aliskiren
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension.<ref name="a2">[https://web.archive.org/web/20070322214927/http://www.cbc.ca/cp/HealthScout/070306/6030611AU.html "First Hypertension Drug to Inhibit Kidney Enzyme Approved".] CBC. 2007-03-06. Archived from the original on 2007-03-22. Retrieved 2007-03-14.</ref> | Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension.<ref name="a2">[https://web.archive.org/web/20070322214927/http://www.cbc.ca/cp/HealthScout/070306/6030611AU.html "First Hypertension Drug to Inhibit Kidney Enzyme Approved".] CBC. 2007-03-06. Archived from the original on 2007-03-22. Retrieved 2007-03-14.</ref> | ||
| - | Aliskiren is an antagonist to renin. | + | Aliskiren is an antagonist to renin.<ref name="a12">PMID:10903938</ref> Renin, the first enzyme in the renin–angiotensin–aldosterone system, plays a role in blood pressure control. It cleaves angiotensinogen to angiotensin I, which is in turn converted by angiotensin-converting enzyme (ACE) to angiotensin II. Angiotensin II has both direct and indirect effects on blood pressure. It directly causes arterial smooth muscle to contract, leading to vasoconstriction and increased blood pressure. Angiotensin II also stimulates the production of aldosterone from the adrenal cortex, which causes the tubules of the kidneys to increase reabsorption of sodium, with water following, thereby increasing plasma volume, and thus blood pressure.<ref name="a12">PMID:10903938</ref |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:38, 20 December 2023
| |||||||||||
References
- ↑ "First Hypertension Drug to Inhibit Kidney Enzyme Approved". CBC. 2007-03-06. Archived from the original on 2007-03-22. Retrieved 2007-03-14.
- ↑ 2.0 2.1 Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grutter MG. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000 Jul;7(7):493-504. PMID:10903938
